WA manufacturer’s stunning 377 per cent share price rise

Shares in nerve growth therapy developer Orthocell (ASX: OCC) have surged 377 per cent on positive news from clinical trials of its CelGro tissue repair device. The company, which developed and manufactures CelGro at its internationally-approved facility in Perth, passed a critical trial with patients with damaged nerves. The first four patients to receive surgery…

Both parties fall short on R&D in 2019 election

If you were thinking of casting your vote in the 2019 federal election on the basis of the innovation policies of the major parties you now have a choice between proven failure and halfhearted and misguided action. As I have argued, the Coalition’s research and innovation policies have been missing in action, with our national…